Morrison Robert J, Kashlan Khaled N, Flanangan Colleen L, Wright Jeanne K, Green Glenn E, Hollister Scott J, Weatherwax Kevin J
Department of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.
Clin Transl Sci. 2015 Oct;8(5):594-600. doi: 10.1111/cts.12315. Epub 2015 Aug 3.
Three-dimensional (3D) printing, or additive manufacturing, technology has rapidly penetrated the medical device industry over the past several years, and innovative groups have harnessed it to create devices with unique composition, structure, and customizability. These distinctive capabilities afforded by 3D printing have introduced new regulatory challenges. The customizability of 3D-printed devices introduces new complexities when drafting a design control model for FDA consideration of market approval. The customizability and unique build processes of 3D-printed medical devices pose unique challenges in meeting regulatory standards related to the manufacturing quality assurance. Consistent material powder properties and optimal printing parameters such as build orientation and laser power must be addressed and communicated to the FDA to ensure a quality build. Postprinting considerations unique to 3D-printed devices, such as cleaning, finishing and sterilization are also discussed. In this manuscript we illustrate how such regulatory hurdles can be navigated by discussing our experience with our group's 3D-printed bioresorbable implantable device.
在过去几年中,三维(3D)打印技术,即增材制造技术,已迅速渗透到医疗器械行业,创新团队利用该技术制造出具有独特成分、结构和定制性的器械。3D打印所具备的这些独特能力带来了新的监管挑战。3D打印器械的定制性在起草供美国食品药品监督管理局(FDA)考虑市场批准的设计控制模型时引入了新的复杂性。3D打印医疗器械的定制性和独特制造工艺在满足与制造质量保证相关的监管标准方面带来了独特挑战。必须解决一致的材料粉末特性以及诸如构建方向和激光功率等最佳打印参数,并将其传达给FDA以确保高质量的构建。还讨论了3D打印器械特有的打印后注意事项,如清洁、精加工和灭菌。在本手稿中,我们通过讨论我们团队在3D打印生物可吸收植入式器械方面的经验,说明如何跨越这些监管障碍。